The control of vascular tone during exercise is highly complex and integrated.
Introduction
The regulation of vascular smooth muscle tone during dynamic exercise is characterized by complex integration and redundancy, thus facilitating a tight coupling between metabolic rate and oxygen (O 2 ) delivery. An extensive list of candidate vasoactive substances has been identified and investigated and among these, substantial interest has been focused on the potential contribution of nitric oxide (NO). Despite intensive research efforts the role(s) of NO in skeletal muscle resistance vessel dilation during exercise has not been elucidated clearly (for excellent reviews see 5, 16, 25, 29) .
A common experimental method for examining the contribution of NO to active skeletal muscle hyperemia is to inhibit NO synthase (NOS) at rest and report measures of blood flow and/or vascular conductance (VC) during subsequent exercise. Using this method, there is evidence for at least a moderate contribution of NO (~10-35% reductions in blood flow and/or VC; 6, 12, 14, 22) . However, the literature is equivocal on this issue as studies have also demonstrated no effects of NOS inhibition (8, 9, 11, 24, 26, 30) . Specifically, our laboratory has demonstrated that infusion of the NOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME) prior to exercise onset in the presence of prior cyclooxygenase (COX) inhibition significantly reduced blood flow (~25% reduction; 14) and VC (~33% reduction; 22) when compared to COX inhibition alone in rat hindlimb muscles in a fiber-type dependent manner (i.e., primarily in the highly oxidative muscles and muscle parts).
One putative confound to data interpretation when NOS blockade is performed prior to exercise onset is that reductions in blood flow and/or VC measured during subsequent exercise may simply parallel reductions in resting flow (9) . It is possible that the observed magnitude or fiber-type dependency of the NO contribution to the exercise hyperemic response differs substantially depending on the timing of the NOS inhibition. Experimental protocols that administer NOS inhibition during contractions may more clearly characterize the NO contribution to exercise hyperemia per se. In this regard, Hussain et al. (15) reported that NOS inhibition administered during electrically-induced contractions of the canine diaphragm partially reversed the contraction-induced vasodilation. In humans, NOS blockade administered independently (without COX inhibition) significantly attenuated forearm muscle blood flow and VC during handgrip exercise (7, 28) but not during isolated knee extensor exercise (26) .
Conversely, combined COX and NOS inhibition administered during knee extensor exercise reduced femoral artery blood flow (19) which suggests that substantial redundancy exists between the NOS and COX systems.
Despite these conclusions, a protocol administering NOS inhibition during exercise has yet to examine specifically whether NO contributes to the exercise hyperemia in the locomotor muscles during conscious whole-body dynamic exercise. Moreover, studies of bulk limb or isolated muscle flow cannot address whether the muscle fiber-type dependency of NO observed when NOS inhibition is administered prior to exercise exists when NOS inhibition is performed during exercise. Therefore, the purpose of the current study was to build on previous work and determine the effects of NOS blockade administered during conscious submaximal treadmill exercise on total and regional (inter-and intramuscular) skeletal muscle blood flow and VC in the rat hindlimb. We tested the hypotheses that L-NAME, infused during submaximal treadmill exercise in the presence of prior COX inhibition via indomethacin, would reduce total hindlimb muscle blood flow and VC compared to COX inhibition alone and that the reductions in blood flow in the individual muscles or muscle parts would be fiber-type dependent such that the highly oxidative muscles and muscle parts would exhibit the greatest reductions in flow and VC.
Methods

Animal selection and care
A total of 17 adult female Wistar rats (age: 3-4 months, body weight: 257 ± 5 g) were used in this study. Rats were housed 2 per cage and maintained on a 12:12 hour light-dark cycle with food and water available ad libitum. All rats were familiarized with running on a motordriven treadmill over a ~2 week period in which rats exercised for ~5 min/day at a speed of 20 m/min up a 10% grade. All experiments were conducted under the guidelines established by the National Institutes of Health and approved by Kansas State University's Institutional Animal Care and Use Committee.
Surgical procedures and experimental protocol
After it was established that all rats were proficient runners (i.e., able to run continuously for a minimum of 5 minutes), the animals were randomly assigned to either an experimental (n = 10) or time control (n = 7) group. All animals were initially anesthetized with 5% halothane gas.
While being maintained on a 2% halothane-oxygen mixture, one catheter (PE-10 connected to PE-50, Clay Adams Brand, Sparks, MD) was placed in the ascending aorta via the right carotid artery and another was placed in the caudal (tail) artery, as described previously (23) . Both catheters were tunneled subcutaneously to the dorsal aspect of the cervical region and exteriorized through a puncture wound in the skin. After closure of the incisions, anesthesia was terminated and the animal was given ≥ 2 hours to recover.
Subsequent to the recovery period, the final protocol was initiated. 5 mg · kg -1 of body weight of indomethacin (Sigma Chemical, St. Louis, MO), a COX inhibitor, was administered to each rat via the tail artery catheter. Indomethacin was administered to limit the redundancy within the vasodilatory system which may mask the physiological NO contribution (see DISCUSSION for details) and to facilitate the integration of the current results with our previous report of NOS inhibition prior to exercise (14) . Each rat was then placed on the treadmill and, after a period of stabilization (~2 hours after instrumentation), 10 µg · kg -1 of acetylcholine (Ach:
Sigma Chemical, St. Louis, MO) was administered via the carotid artery catheter. The subsequent peak hypotensive response to Ach injection was measured and recorded from the tail artery catheter in order to determine the efficacy of endothelium-dependent vasodilation.
After Ach injection, the tail artery catheter was connected to a 1 ml plastic syringe which ) and is identical to the exercise protocol employed when L-NAME was administered prior to moderate-intensity exercise (14) .
The rat was then required to exercise steadily for another 5 minutes. After ~5.5 minutes of total exercise time, blood withdrawal from the tail artery catheter was initiated at a rate of 0.25 ml · seconds after the injection (~6 minutes of total exercise time), exercise was terminated and each rat was allowed a minimum of 60 minutes to recover.
After recovery from the initial exercise bout, a second bout of exercise was initiated, and the speed of the treadmill was increased progressively during the next 30 seconds to a speed of 20 m/min (10% grade). The rat was then required to exercise steadily for another ~2.5 minutes.
Prior to the 3 minute mark, 10 mg · kg -1 of the L-arginine analogue N G -nitro-L-arginine-methylester (L-NAME: Sigma Chemical, St. Louis, MO) was then infused into the tail artery catheter over a 10 second period while HR and MAP were monitored continuously from the carotid artery catheter. After ~5.5 minutes of total exercise time, a second microsphere injection (differently labeled from the first injection) was performed as described above for the first bout of exercise. Exercise was then terminated and each rat was given ~5-10 minutes to recover.
After this recovery period, a second Ach injection was performed and the hypotensive response was measured. This response was then compared to that obtained before the control exercise bout to determine the degree of NOS inhibition attained by L-NAME. The radioactivity of each tissue was determined on a gamma scintillation counter (Packard Auto Gamma Spectrometer, model 5230, Downers Grove, IL). Taking into account cross-talk between isotopes, blood flows to each tissue were determined using the reference sample method (23) and expressed as milliliters per minute per 100 g of tissue (ml · min -1 · 100
. Adequate mixing of the microspheres was evaluated and verified in all 17 animals for each injection by the demonstration of a <15% difference between blood flow to the right and left kidneys (mean difference exercise bout 1: 9.5 ± 2.2%, exercise bout 2: 8.7 ± 2.2%) and/or to the right and left hindquarter musculature (mean difference exercise bout 1: 7.9 ± 1.8%, exercise bout 2: 8.8 ± 1.3%). Blood flow results were also normalized to MAP and expressed as VC (ml · min -1 · 100 g -1 · mmHg -1 ).
Time control experiments
Time control studies (n = 7) were performed to determine the degree of reproducibility between the hindlimb blood flow and VC measured during the two bouts of exercise described in the present investigation. Control rats were required to perform the experimental protocol described above with the exception that L-NAME administration was excluded during the second bout of exercise.
Statistical analyses
HR, MAP, muscle blood flow, and tissue VC measured during the first and second bouts of exercise were compared using two-tailed paired Student's t-tests. A one-way repeated measures ANOVA was used to compare minute MAP values within exercise bouts to determine magnitude and time course of MAP increase after L-NAME administration during exercise. A ztest was used to determine if the relative changes in blood flow between exercise bouts 1 and 2
for time control and experimental rats were different from zero. Pearson's product-moment correlations were performed to determine whether the absolute and relative reductions in blood flow (Δ blood flow) and VC (Δ VC) in the individual muscles or muscle parts produced by L-NAME administration during exercise were correlated with their estimated fiber type composition. Values are presented as means ± SEM. Significance was accepted at the P < 0.05 level.
Results
Effects of L-NAME infusion during exercise on blood flow and VC
Total hindquarter muscle blood flow (control: 123 ± 10, L-NAME: 103 ± 7 ml · min -1 · 100 g -1 ) and VC (control: 0.95 ± 0.09, L-NAME: 0.63 ± 0.05 ml · min -1 · 100 g -1 · mmHg -1 ) were reduced (P < 0.05 for both) 16% and 34%, respectively, when L-NAME was administered in the exercising rat (Fig. 1 ). Blood flow was attenuated significantly (P < 0.05) in 11 of the 28 muscles or muscle parts in the rat hindlimb with the administration of L-NAME during exercise (Table 1) . When the data were expressed as VC, significant reductions were observed after L-NAME in 20 of the 28 different muscles or muscle parts (Table 1) .
Correlations with muscle fiber-type composition
There was no correlation between the absolute Δ blood flow in the individual muscles or muscle parts after L-NAME and percent sum of type I and IIa fibers (Fig. 2) . Indeed, there was a significant negative correlation (r = 0.40, P < 0.05) between the relative Δ blood flow and the percent sum of type I and IIa fibers such that little or no effect of L-NAME was observed in the oxidative muscle regions (Fig. 2) . The absolute Δ VC correlated significantly (r = 0.51, P < 0.01) with the percent sum of type I and IIa fibers found in the individual muscles or muscle parts of the rat hindlimb, however, when expressed in relative terms the direction of the correlation with type I and IIa fibers (r = 0.40, P < 0.05) was reversed (Fig. 3) .
Effects of L-NAME on HR, MAP and hypotensive responses to Ach injections
Pre-exercise HR and MAP were similar between the first and second bouts of exercise (Table 2) . HR increased from resting values during the two exercise regimens and to a similar degree, however, the intra-arterial administration of L-NAME during the second bout of exercise while the animal was running on the treadmill produced a significant (P < 0.05) increase in MAP and decrease in HR (Fig. 4 , Table 2 ). Importantly, the increase in MAP was evident within <10 seconds of L-NAME infusion and the entirety of the increase was complete within ~2.5 minutes (i.e., by the time the microsphere injection was performed, Fig. 4 ). The hypotensive response (absolute and relative change in MAP) produced by the injection of Ach was blunted significantly following the administration of L-NAME (Fig. 5) , demonstrating that significant NOS inhibition had been achieved in the exercising rats.
Time controls
Results from the time control animals (n = 7) demonstrated that HR, MAP, and the hypotensive response to Ach injections were not different between exercise bout 1 and 2. Total hindlimb musculature blood flow (exercise bout 1: 109 ± 9, exercise bout 2; 110 ± 11 ml · min -1 · 100 g -1 , P > 0.05) and VC (exercise bout 1: 0.83 ± 0.08, exercise bout 2; 0.81 ± 0.09 ml · min -1 · 100 g -1 · mmHg -1 , P > 0.05) were not different between the first and second exercise bouts (Fig.   6 ). Moreover, blood flow to all 28 individual skeletal muscles or muscle parts examined in this study was not different (P > 0.05) between the first and second exercise bouts. This demonstration that both the hemodynamic and the skeletal muscle blood flow responses were reproducible between the repeated bouts of exercise in the time control animals allows for the direct comparison of these variables in the rats that were subjected to the administration of L-NAME during the second exercise bout.
Discussion
The vasoregulatory pathways controlling vessel tone and blood flow (and therefore O 2 delivery) at rest, during dynamic blood flow adjustments, and during the exercising steady-state may vary markedly (3, 10, 13). As a result, attenuations in skeletal muscle blood flow and VC measured during exercise subsequent to NOS inhibition administered prior to the exercise bout, may only identify NO as a modulator of resting vasomotor control. Accordingly, there are two novel findings of the present investigation: 1) consistent with our hypothesis, in the presence of prior COX inhibition, the potent NOS inhibitor L-NAME administered during submaximal whole-body exercise significantly reduced total rat hindlimb muscle blood flow and VC compared to that observed with COX inhibition alone, and 2) there was a positive correlation between the reductions in VC after L-NAME and the percent sum of type I and IIa muscle fibers but, surprisingly, the fiber-type dependency of muscle blood flow reductions observed with NOS inhibition administered prior to submaximal treadmill exercise (14) was completely abolished when NOS inhibition was administered during exercise.
Comparison with previous research
Recently, it has been suggested that the search for a single key vasodilating substance is futile and the nature of the vasoregulatory system is one of redundancy and synergy (3). While NOS inhibition has identified a role for NO in regulating active muscle hyperemia in animal models with some consistency, whether NO contributes importantly to the hyperemic response in human locomotor muscle during dynamic exercise has been a point of major contention in the literature. Possible reasons for this discrepancy have been discussed in detail elsewhere (see relevant discussions in 7, 25, 28, 29). Two major considerations are pertinent to the current study. First, it is uncertain whether, or to what degree, NOS inhibitors administered at rest actually reach the specific vessels within the muscles recruited during a subsequent exercise bout (28) . This issue is circumvented by performing NOS inhibition during exercise when a substantial proportion of the cardiac output is directed to the working muscles (27) . While it may be argued that performing NOS inhibition prior to exercise is a more appropriate model of exercise conditions in disease states in which reduced NO bioavailability is implicated in the underlying pathology, performing NOS inhibition during exercise is warranted given that different vascular control mechanisms may be active at rest, during the onset of contractions and during the contracting steady state (3, 10) . Thus, the current protocol lends direct mechanistic insight into integrated NO-mediated vascular control during exercise in healthy subjects.
Second, experimental approaches using combined NOS and COX inhibition (as in the current study) and independent NOS inhibition have been used to examine the physiological role(s) of NO and it is important to recognize that these dissimilar approaches answer very specific and different research questions. For example, there is strong evidence that supports substantial redundancy between the NOS and COX systems (2, 11, 18, 19, 26) , although this redundancy is not evident in all experimental models (28) . When NOS inhibition is administered independently the COX system may compensate and mask the physiological NO contribution thus presenting ambiguity regarding NO's role in the physiologic hyperemia. In these cases the conclusion is only that the physiological NO signal (as reported in the present study) is not an obligatory phenomenon (9, 26) . Notwithstanding this consideration, it is important to note that both experimental designs (i.e., independent NOS inhibition versus combined COX and NOS inhibition) provide valuable insight into the NO-mediated regulation.
Studies administering either NOS inhibition independently or combined NOS and COX inhibition during muscle contractions have identified NO as a mediator of active muscle bulk hyperemia in the contracting human forearm (7, 28) and leg (2, 19) and isolated canine diaphragm (15) . Consistent with those studies, we currently found 16% and 34% reductions in blood flow and VC, respectively, within the rat hindlimb muscles and defined the regional distribution of that flow within and among locomotory muscles during whole-body dynamic exercise. Moreover, our current findings expand on previous reports from our laboratory in which L-NAME was administered prior to the initiation of submaximal (14) and maximal (22) exercise. Specifically, current results establish clearly that NO is an integral mediator of exercise hyperemia and VC rather than reflecting simply that NO regulates solely basal peripheral vascular tone (Fig. 6 ).
NO and muscle fiber-type composition
A significant limitation of previous investigations that have administered NOS inhibition during contractions is that it has been possible to evaluate only the NO contribution to bulk limb (7, 26, 28) or an individual muscle (15) (20), the isolated perfused rat hindlimb (17) , and intact exercising animals (14, 22) . Presently we reported a correlation between VC and the percent sum of type I and IIa muscle fibers which is consistent with those reports. However, the relationship between oxidative fibers and VC found herein is qualitatively and quantitatively (P < 0.01) different (i.e, less robust fiber-type dependency) versus that found with NOS inhibition prior to exercise (Fig. 7) . Moreover, we found no correlation between muscle-fiber type and the reductions in blood flow induced by L-NAME administration during exercise. This finding is inconsistent with NOS inhibition performed prior to exercise (Fig. 7) and surprising considering that the submaximal treadmill speed utilized is expected to recruit primarily oxidative motor units (1, 4) . Interestingly, the divergence from our previous work (14) appears to result principally from consistent differences occurring within the most oxidative muscles or muscle parts (i.e., all muscles or muscle parts containing greater than ~80% oxidative fibers; the soleus, red portion of the gastrocnemius, vastus intermedius, adductor longus). Of particular interest is that these oxidative regions sustain the largest hyperemic responses and, presumably, a significant portion of L-NAME was directed to these muscles. The present finding identifies that the potential for redundancy within these highly oxidative fibers in enhanced when NOS blockade is performed during versus prior to exercise.
The systemic infusion of L-NAME resulted in significant increases in MAP. Therefore, it was important to analyze the fiber-type correlations expressed as both blood flow and VC.
Although VC is the most appropriate indicator of vessel tone when experimental paradigms result in increases in systemic driving pressure, it is interesting to note that blood flow in the highly oxidative muscle(s) was essentially unchanged after L-NAME infusion ( Fig. 2 and 7 ).
Tschakovsky and Joyner (29) have suggested that when calculated VC is reduced in the face of unchanged blood flow it may represent a normal metabolic autoregulatory response that effectively matches oxygen delivery to oxygen demand. Thus, our data may be interpreted to suggest that a greater ability to match O 2 delivery to O 2 demand is retained in the highly oxidative muscles when NOS is inhibited during versus prior to exercise.
Experimental considerations
As discussed above, in the present investigation we utilized a unique experimental protocol in which the COX inhibitor indomethacin was administered prior to the control exercise bout to limit the potential for vasodilating prostaglandins to mask the physiological NO contribution with L-NAME administration. Therefore, NOS inhibition during the second exercise bout was performed in the presence of previously administered COX inhibition. Our results suggest that NO does have an important role in blood flow regulation under normal physiological conditions. While it is possible that our results may differ if NOS inhibition is administered independently, we believe the current model addresses an important question regarding the physiological NO contribution.
Systemic infusion of L-NAME in the current investigation produced significant increases in MAP (occurring within <10 seconds of infusion, Fig. 3 ) and decreases in HR. As evident in Fig. 4 , the entire effect of L-NAME administration during the second exercise bout on MAP was complete by the time the microsphere injection was performed. Furthermore, Hirai et al. (14) systematically administered doses of L-NAME higher than 10 mg · kg -1 and observed no further effect on either blood flow or the hypotensive response to Ach injection. Although the experimental model used presently precludes the determination of the precise degree of NOS inhibition, these observations suggest strongly that the ability to inhibit NOS in vivo was maximized.
Analysis of the hindlimb musculature blood flow and VC during the two exercise bouts from the experimental and time control rats via repeated measures two-way ANOVA with an a priori comparison produced the same statistical interpretation as performing paired Student's t-tests. We chose to present the results from the t-test comparisons to facilitate clarity of data presentation.
Perspectives and significance
Varying the timing of NOS inhibition with respect to an exercise bout can lend important mechanistic insights into the integrated nature of vascular and blood flow regulation. Based upon NOS inhibition initiated prior to the onset of exercise, it was unclear whether or not subsequent reductions in exercising muscle blood flow resulted from a carry-over of decreased resting conductance. By specifically choosing to initiate NOS inhibition during exercise the present investigation presents clear and unique evidence that NO is a quantitatively important regulator of exercise hyperemia in locomotory muscles during submaximal whole-body exercise.
L-NAME administered during exercise reduced blood flow in 11 of the 28 individual muscles or muscle parts of the rat hindlimb and VC in 20 of the 28 muscles or muscle parts. We found a significant correlation between the change in absolute VC after L-NAME and the percent sum of type I and IIa muscle fibers which is consistent with the observation of fiber-type dependency of the physiological NO signal, however, the strength of this relationship was reduced substantially compared to our previous investigation in which L-NAME was administered prior to exercise.
Moreover, there was no correlation between the absolute reduction in blood flow after L-NAME during exercise and muscle fiber-type composition which differs substantially from the robust fiber-type dependency of NO contribution to blood flow observed when L-NAME is administered prior to exercise (14) . Specifically, the current experimental model unveiled, for the first time, that highly oxidative muscles (i.e., >80% oxidative fibers) demonstrate a marked ability to maintain perfusion levels after L-NAME administration during exercise. , and when L-NAME was administered prior to (ref. 14, n = 6) and during (present study, n = 10) the second exercise bout. * Significantly different from zero. 
